Outcome of Board Meeting Held on 16th July, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Bacil Pharma's Board of Directors met on July 16, 2025 and approved two key leadership changes effective immediately. Mr. Jayesh Ramchandra Patil resigned from the post of Chief Financial Officer (CFO) citing personal reasons, after serving the company for around 18 years. In his place, Ms. Chaitali Kalpataru Shah (DIN: 11167778) has been appointed as the new Executive Director and CFO, bringing experience in finance, accounts, and corporate management. The Board appreciated Mr. Patil's contribution during his long tenure. The new appointee is not debarred by SEBI or any other authority from holding a directorship.
This is a routine top-level leadership transition at a small-cap pharma company with an immediate successor in place, so there is no disruption to operations. Shareholders should note that a senior financial hand has exited, but the new CFO's appointment suggests continuity in financial oversight.